Real-world evidence (RWE) supports the efficacy of Ibrance plus letrozole in breast cancer
- Data published in Breast Cancer Research showed real-world efficacy of palbociclib (Ibrance) in combination with letrozole in women with hormone receptor–positive, HER2-negative metastatic breast cancer versus letrozole alone
- These findings which showed extended overall and progression-free survival (PFS) benefit with the combination represents the first comprehensive comparative effectiveness analysis of outcomes for a CDK4/6 inhibitor in clinical practice
- “Real-world evidence is woven into the fabric of how we innovate and advance care for patients with breast cancer, supporting our randomized clinical trials
- With more than 6 years of patient experience, a positive benefit-risk profile, strong clinical data, and robust real-world data, the totality of evidence solidifies the role of palbociclib plus endocrine therapy as a treatment for patients with metastatic breast cancer.”
Chris Boshoff, MD, PhD, Chief Development Officer, Oncology, Pfizer Global Product Development
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: MAY2021CW001